Stabilitech

Stabilitech Biopharma is applying its patented THERM-SB platform, for the thermo-stabilisation of viruses, vaccines, proteins and biopharmaceuticals, in the development of various technologies including  the OraPro™ oral delivery system for biopharmaceuticals and vaccines, which:

• enables oral administration of non-replicating vector
• enables repeat administration with the same vector carrying the same or new payload
• enables transient biopharmaceutical production induced within the human/patient gut
• is suitable for vaccines, therapeutic proteins, enzyme replacement, etc
• forms a thermally stable oral capsule
• allows for the re-use of a vector for new developments / enables re-use of large parts of the regulatory dossier

Therm-SB is a formulation of simple sugars and non-toxic small molecules in discrete concentrations and ratios that are mixed with the vaccine during the fill-finish process.

The company has partnerships with several pharma companies including GSK and it seeks additional partnerships for the development of products based on its THERM-SB platform and the OraPro™ technology.

What's this?